CRBU - Company ID 0001619856
The table below shows Caribou Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $11.16M | $9.99M | $34.48M | $13.85M | $9.60M | $12.36M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $109.44M | $130.15M | $112.08M | $82.23M | $52.26M | $34.42M |
| SG&A |
Caribou Biosciences, Inc. reported annual revenue of $11.16M for fiscal year 2025. That is up 11.7% from $9.99M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $5.79M (FY 2019) to $11.16M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $37.91M |
| $46.46M |
| $38.46M |
| $38.02M |
| $24.32M |
| $14.06M |
| Operating income | -$148.34M | -$166.62M | -$116.06M | -$106.40M | -$66.98M | -$36.12M |
| Income tax | -$550.00K | -$9.00K | $193.00K | $70.00K | $321.00K | -$1.82M |
| Net income | -$148.13M | -$149.10M | -$102.07M | -$99.42M | -$66.92M | -$34.31M |
| EPS (diluted) | -$1.59 | -$1.65 | -$1.38 | -$1.64 | -$2.11 | - |